Last reviewed · How we verify
COVID-19 prevention in individuals 6 months through 4 years of age — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| bivalent BNT162b2 (original/Omi BA.4/BA.5) | bivalent-bnt162b2-original-omi-ba-4-ba-5 | Pfizer | mRNA vaccine | SARS-CoV-2 virus | ||
| BNT162b6 Bivalent (Original/OMI BA.4/BA.5) | bnt162b6-bivalent-original-omi-ba-4-ba-5 | Pfizer | vaccine | SARS-CoV-2 spike protein |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in COVID-19 prevention in individuals 6 months through 4 years of age
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in COVID-19 prevention in individuals 6 months through 4 years of age:
- COVID-19 prevention in individuals 6 months through 4 years of age treatment updates — RSS
- COVID-19 prevention in individuals 6 months through 4 years of age treatment updates — Atom
- COVID-19 prevention in individuals 6 months through 4 years of age treatment updates — JSON
Cite this brief
Drug Landscape (2026). COVID-19 prevention in individuals 6 months through 4 years of age — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age. Accessed 2026-06-10.
Related
- COVID-19 prevention in individuals 6 months through 4 years of age full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing